We note however that in terms of clinical applications, PD-1 inhibition is associated with adverse events such as thyroid dysfunction and pneumonitis, CTLA-4 inhibition is closely associated with colitis and hypophysitis, and both drugs are associated with rash and hepatitis [91], and ENZ adverse events includes seizure and ischemic heart disease. Here, CTLA4 is linked to colitis.